NovoCure (NVCR) Income from Continuing Operations (2014 - 2026)
NovoCure (NVCR) posted Income from Continuing Operations of 15658000.0 for Q2 2026, up 77.99% sequentially from 71138000.0 in Q1 2026, and up 60.99% YoY from 9726036.24 in Q2 2025.
NovoCure (NVCR) Income from Continuing Operations (2014 - 2026) Analysis & Trends
NovoCure has reported Income from Continuing Operations for 13 years, with the latest figure at 15658000.0 in Q2 2026.
- Quarterly Income from Continuing Operations rose 60.99% year-over-year to 15658000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 148565000.0 (up 13.09% YoY) and the FY2025 annual result came in at 136227000.0, up 19.21% from the prior year.
- Income from Continuing Operations improved to 15658000.0 in Q2 2026 per NVCR's latest filing, from 71138000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 4647000.0 in Q1 2022 and troughed at 71138000.0 in Q1 2026.
- A 5-year average of 38401500.0 and a median of 37286500.0 in 2022 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2025: Income from Continuing Operations slumped 1041.83% in 2023, then surged 62.84% in 2025.
- Over 5 years, Income from Continuing Operations stood at 37303000.0 in 2022, then fell by 26.21% to 47079000.0 in 2023, then plunged by 40.02% to 65922000.0 in 2024, then soared by 62.84% to 24499000.0 in 2025, then surged by 36.09% to 15658000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 15658000.0, 71138000.0, and 24499000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | 1.28 Bn |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | 905.00 Mn |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | 241.40 Mn |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | 249.10 Mn |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | 574.00 Mn |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | 1.04 Bn |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | 201.00 Mn |
| 10 | NovoCure | 1.99 Bn | 1.55 Bn | 142.48 Mn | -15.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.66 Mn |
| Mar 31, 2026 | -71.14 Mn |
| Dec 31, 2025 | -24.50 Mn |
| Sep 30, 2025 | -37.27 Mn |
| Jun 30, 2025 | -40.14 Mn |
| Mar 31, 2025 | -34.32 Mn |
| Dec 31, 2024 | -65.92 Mn |
| Sep 30, 2024 | -30.57 Mn |
| Jun 30, 2024 | -33.38 Mn |
| Mar 31, 2024 | -38.76 Mn |
| Dec 31, 2023 | -47.08 Mn |
| Sep 30, 2023 | -49.49 Mn |
| Jun 30, 2023 | -57.42 Mn |
| Mar 31, 2023 | -53.06 Mn |
| Dec 31, 2022 | -37.30 Mn |
| Sep 30, 2022 | -26.58 Mn |
| Jun 30, 2022 | -24.01 Mn |
| Mar 31, 2022 | -4.65 Mn |
| Dec 31, 2021 | -26.46 Mn |
| Sep 30, 2021 | -13.12 Mn |